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The increased risk of coronary heart disease associated with nephrotic
syndrome. Patients with nephrotic syndrome (NS) are believed to be at
increased risk of atherosclerosis and coronary heart disease (CHD),
although existing evidence for this association has not been persuasive.
The risk of CHD among 142 persons with NS documented by protein-
uria 3.5 g daily was compared with that among 142 matched controls
randomly selected from the membership of a large Northern California
health plan. Controls were matched for sex, year of birth, and presence
in the health plan when the referent case was diagnosed. No diabetics
were included in this study. Mean follow-up for nonfatal CHD events
was 5.6 years for NS subjects and 11.2 years for controls. Among the
NS subjects myocardial infarction (MI) developed in 11, and there were
58 deaths, seven because of CHD. Among the controls, there were four
MIs and 10 deaths, three because of CHD. In matched-pair analysis,
there were 11 MIs among NS subjects and none among controls [P =
0.001, lower bound of 95% confidence interval for relative risk (CI),
2.8]. In an unmatched analysis adjusted for hypertension and smoking
at diagnosis of NS, the relative risk of MI was 5.5 (95% CI 1.6 to 18.3)
and the relative risk of coronary death was 2.8 (95% CI 0.7 to 11.3).
Omitting data of NS subjects with minimal change disease and systemic
lupus erythematosus yielded similar results. These data suggest that
persons with NS are at increased risk of CHD.
potentially confounding factors (such as hypertension), and
difficulty of obtaining sufficiently long-term follow-up. We used
the computer-stored files and hospital records of a large prepaid
health plan to investigate incidence of CHD among patients
diagnosed with NS.
Methods
The Kaiser Permanente Medical Care Program of Northern
California (KPMCP) is a prepaid health plan that had about 1.8
million members in 1980. Comprehensive health services have
been offered by the program since the late 1940s. Age and sex
composition of the membership is similar to that of the United
States Census population in the area, and the membership is
representative of diverse racial, occupational, educational, and
income groups [14, 151.
NS subject selection
The nephrotic syndrome (NS) is characterized by heavy
proteinuria and a variable tendency toward hypoalbuminemia,
hyperlipidemia, and edema [1]. Patients with NS are assumed to
be at increased risk for atherosclerosis and coronary heart
disease (CHD), probably because of NS-associated hyperlipid-
emia. The most frequent of these abnormalities is hypercholes-
terolemia and, as the disease progresses in some patients,
hypertriglyceridemia [2—51. Although hyperlipidemia can lead
to atherosclerosis, CHD has not been proven to be more
common in persons diagnosed with NS than in the general
population. Several case studies suggested increased risk of
CHD among patients with NS [6, 7], but other studies [8—li]
showed no increased risk of CHD among NS patients. These
studies were criticized for having small sample sizes, ill-defined
comparison groups [12, 13], or incomplete documentation of
CHD among subjects [131.
Among the major challenges in studying the association
between NS and CHD are: need for a large number of NS
patients and an appropriate control group, need to adjust for
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Patients with clinically diagnosed NS were identified from the
hospital discharge records of all Kaiser Foundation Hospitals in
Northern California by using computer-stored files dating from
1976 to 1981 and manual review of hospital discharge logs
dating from before 1976 (581 ICDA, 8th ed.) [16] (581.0-.9,
ICD-9-CM 9th ed.) [17]. The criterion for confirming the diag-
nosis of NS was proteinuria of 3.5 g daily. The presence of
hypoalbuminemia (serum albumin <3.0 mgldl), hypercholester-
olemia, and hypertriglyceridemia were also recorded but were
not considered essential for the diagnosis [1]. Patients who had
ever been diagnosed with diabetes mellitus and those younger
than 15 years at NS diagnosis were excluded. We identified 155
persons diagnosed with NS between 1961 and 1981 who were
alive on 1/1/71. Thirteen of these had evidence of CHD before
diagnosis and were excluded from the main analyses.
Control subject selection
From computer-stored ifies of the general health plan mem-
bership, which were only available from 1971 onward, we
selected one control subject for each NS subject. Control
subjects were randomly selected from all eligible members who
matched research subjects by sex and by age (within 5 years)
and who were members of the health plan at NS diagnosis. We
excluded potential control subjects whose medical records
showed any evidence of kidney disease or diabetes.
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Data collection
We reviewed the entire inpatient and outpatient record of
each subject for the following demographic information: type
and date of diagnosis of kidney disease; whether kidney biopsy
was done; serum creatinine determinations; quantification of
urinary protein excretion and cholesterol levels; date of onset
and mode of treatment of end-stage renal disease (ESRD) when
it occurred; smoking history; presence and date of onset of
hypertension; and evidence of CHD. Hypertension was defined
as three or more blood pressure recordings of  155/95 mm Hg.
Presence of CHD was determined by: (1) occurrence of
myocardial infarction (MI); (2) a physician's diagnosis of angina
pectoris or coronary insufficiency; (3) an abnormal electrocar-
diogram (ECG), read as "probable or definite ischemia" ac-
cording to the Minnesota Code [181; or (4) death secondary to
CHD. All ECGs were read by an investigator who was blind to
the NS status of the subject. The clinical diagnosis of MI was
confirmed by abnormal ECG tracing and enzyme elevation.
We obtained information on date and cause of death from the
medical record. Deaths were also independently confirmed by
linking the files of research and control subjects to the Califor-
nia Mortality Linkage System (CAMLIS), a State of California
registry of deaths since 1960 [19]. A final assessment of the
cause of death was made on the basis of medical records, death
certificates, and available autopsy records by an investigator
who was blind to the NS status of the subjects.
Analysis
For analysis, we defined the follow-up period for nonfatal
CHD events as the period from date of initial NS diagnosis (and
the equivalent date for corresponding control subjects) to date
of outcome (such as MI, ESRD, death), date of the last contact
recorded in the medical record (up to 2/16/87), or termination of
KPMCP membership, whichever came first. For fatal CHD
events, we began follow-up on 1/1/71, because subjects were
selected from the computer-stored 1971 membership file and,
thus, by definition, had to be alive on that date. Follow-up
ended at death or on 6/30/86, the date covered by the death
search. More control subjects than NS subjects were reviewed
later in the study period, which contributed to the longer total
follow-up for control subjects than for NS subjects. We consid-
ered deaths of NS subjects in whom ESRD developed during
follow-up to be "renal deaths," and follow-up was ended on the
date of first dialysis.
For CHD outcomes, we first did a survival analysis using a
matched-pair design in which follow-up for both members of
each pair stopped at the end of follow-up for either the NS
subject or the control subject. To estimate relative risk (RR),
we calculated the ratio of events among NS subjects to events
among control subjects. We determined statistical significance
using a binomial test and calculated binomial confidence inter-
vals. We next calculated rates of CHD outcomes per person-
years of follow-up and then examined the risk of CHD events
using proportional hazards models and adjusting for the pres-
ence of hypertension from five years before through the year of
diagnosis and for current smoking status at diagnosis.










Mean age at diagnosis years 142 43.7 142 43.0
Percentage male 142 62.7 142 62.7
Mean follow-up years 142 5.6 142 11.2
Mean mortality follow-up 142 7.8 142 10.9
years
Current smokers at diagnosis 117 43.6 104 46.2
%
History of hypertension at 141 29.8 142 9.2
diagnosisa %
Mean cholesterol level (mg/dl) 109 371 13 27 220 8
SE at diagnosis'
Maximum cholesterol level" 109 412 16 27 222 8
(mg/dl) SE at diagnosis
a History of hypertension ( 155/95 on 3 occasions) from 5 years
before through the year of NS diagnosis and corresponding dates for
matched comparison group.b Cholesterol value recorded from one year before to six months after
date of NS diagnosis and on corresponding dates for matched compar-
ison group.
Results
NS and control subjects were closely matched for age and sex
(Table 1). Six NS subjects and corresponding control subjects
were younger than 18 years of age; the youngest was 15 years of
age. Far more NS than control subjects had an outcome event
during follow-up; the mean follow-up for nonfatal CHD events
was 5.6 years for NS subjects and 7.8 years for mortality.
Follow-up for the mortality analysis was longer because some
deaths occurred after subjects left the KPMCP. Although the
proportion of smokers was similar in each group, hypertension
at the time of NS diagnosis was more frequent in NS subjects (P
0.001). For subjects whose cholesterol level was recorded
around the time of NS diagnosis, the mean and maximum
cholesterol levels recorded within one year before to six months
after the diagnosis were significantly (P 0.001) higher for NS
subjects than for controls. All but one of these 109 NS subjects
had cholesterol levels >220 mg/dl (5.69 mmol/liter) during this
1 '/2 year period. An additional 16 NS subjects had recorded
serum cholesterol levels >220 mg/dl (5.69 mmollliter) at other
times during the follow-up period. The other 17 had either lower
levels [4] or no recorded values. When compared with the 125
NS subjects with recorded values >220 mg/dl (5.69 mmol/liter),
these 17 were more likely to be female and younger and to have
shorter follow-up and more nonfatal CHD events. None of
these differences was statistically significant. Among 135 NS
subjects with a recorded serum albumin level, 107 (79.3%) had
recorded values <3 mg/dl. Triglyceride values were not re-
corded frequently enough to provide useful data.
Membranous nephropathy was diagnosed in about 28% of
research subjects (Table 2). Men predominated in all etiologic
groups except the systemic lupus erythematosus (SLE) group.
The category of glomerulonephritis (GN) included eight NS
cases with mesangial proliferative GN diagnosed at biopsy,
seven cases of membranoproliferative ON, and one case each
of rapidly progressive GN and IgA nephropathy. The category
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Table 2. Distribution of renal diagnoses and frequency of biopsies of
NS subjects







Membranous 40 (28.2) 40 (100.0) 75.0 46.0
nephropathy
Minimal change disease 17 (12.0) 17 (100.0) 58.8 43.4
Glomerulonephritis 30(21.1) 21(70.0) 56.7 40.1
Focal glomerulonephritis 9 (6.3) 9 (100.0) 66.7 45.0
Systemic lupus 11(7.7) 6 (54.6) 18.2 46.7
erythematosus
Amyloidosis 4 (2.8) 2 (50.0) 75.0 55.3
Multiple myeloma 4 (2.8) 1 (25.0) 50.0 50.5
Other 6 (4.2) 2 (33.3) 50.0 42.8
Unknown 21(14.8) 1 (4.8) 76.2 42.4
Total 142 (100.0) 99 (69.7) 62.7 43.7
Table 3. Causes of death among NS subjects and their matched
controls
Cause of death NS subjects Controls
Renal disease 32 1
CHD 7 3
Cancer 3 4
Pneumonia/respiratory disease 4 0
Stroke 2 1
Aortic aneurysm 1 0
Intestinal ischemia 1 0
Collagen vascular disease 2 0
Amyloidosis 2 0
Hypertensive disease 1 0
Trauma 1 0
Arrhythmia without CHD 1 0
Congestive heart failure 0 1
Other 1 0
Total 58 10
labeled "other" included two cases of primary hypertensive
disease (1 biopsied), two cases of gold-associated nephropathy,
and one case each of hereditary nephritis and pregnancy-
associated nephropathy. Seventy percent of all diagnoses were
confirmed by kidney biopsy.
At the end of the period of observation, 84 (59.2%) of the 142
NS subjects were alive, 29 (20.4%) had died, and ESRD had
developed with hemodialysis begun in 29 (20.4%); all the deaths
were confirmed by death certificate. Of the 142 control subjects,
10 (7.0%) died; death certificates were available for all but one,
in which autopsy data were available. Causes of death are
detailed in Table 3.
Hemodialysis was initiated in 29 of the 32 NS subjects in
whom ESRD developed. Although the date of first dialysis for
ESRD was used as the end of follow-up, we tallied outcomes
after ESRD. At the end of the study, 14 persons had died, and
death certificates were available for all of them. The cause of
death was listed in nine cases as chronic renal failure, and in
one case each as SLE, amyloidosis, ruptured aortic aneurysm,
pericarditis, and multiple myeloma. No CHD deaths were
recorded on the death certificates.
In the matched-pair analysis, 11 MIs occurred among NS
subjects and none occurred among control subjects (P = 0.001;
Table 4). Adding other nonfatal CHD outcomes to MIs still














MI 11 0 0.0010 — 2.8
MI + AP + CI 13 3 0.0213 4.3 1.3—19
MI + AP + CI 17 3 0.0026 5.7 1.7—24
+ ECG
Deaths (all) 56 5 <0.0001 11.2 4.3—32
Deaths (CHD) 7 2 0. 1797 3.5 0.8—19
Abbreviations are: AP, angina pectoris; CHD, coronary heart dis-
ease; CI, coronary insufficiency; ECG, abnormal ECG (probable isch-
emia); MI, myocardial infarction.









No, py No. py Unadjusted Adjusteda interval
MI II 14.9 4 2.6 5.8 5.5 1.6—18.3
MI + AP 14 19.2 8 5.4 3.2 2.7 1.1—7.0
+ CI
MI + AP 18 25.2 13 8.9 3.1 2.3 1.0—5.2
+ CI +
ECG
Deaths 58 52.2 10 6.5 7.7 7.2 3.6—14.2
(all)
Deaths 7 6.3 3 1.9 3.1 2.8 0.7—11.3
(CHD)
Abbreviations are: AP, angina pectoris; CHD, coronary heart dis-
ease; CI, coronary insufficiency; ECG, abnormal ECG (probable isch-
emia); MI, myocardial infarction; py, person-years.
a Adjusted for current smoking and hypertension at diagnosis of NS
showed a highly significant difference (P = 0.003). The differ-
ence in overall mortality was marked; there were seven coro-
nary deaths among NS subjects compared with two in the
control group (P = 0.180). As reflected in the analysis based on
person-years of follow-up, which takes the full period of fol-
low-up into consideration, 11 MIs occurred among persons with
NS and four occurred among control subjects (Table 5). Pro-
portional hazards models revealed a relative risk of 5.8, which
decreased slightly, to 5.5 (95% CI 1.6 to 18.3), when adjusted
for hypertension and smoking. When we combined MIs with
other nonfatal CHD outcomes, the adjusted RR was 2.3 (95%
CI 1.0 to 5.2). CHD was not diagnosed in either NS or control
subjects younger than 18 years of age. The adjusted RR of
coronary death was 2.8 (95% CI 0.7 to 11.3), but the risk of
dying of any cause, including renal disease, was seven times
greater for NS subjects than for control subjects.
Because of concern about both the lower risk of CHD in
patients diagnosed with minimal change disease and the inde-
pendent risk of CHD in patients with SLE, we repeated the
analysis and excluded the 29 NS subjects with these diagnoses
and the corresponding control subjects. The RR estimates were
substantially the same by both matched and unmatched analy-
ses.
Discussion
This study provides evidence that NS is associated with an
increased risk of CHD. We estimate that the risk of myocardial
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infarction is between five and six times higher for persons with
NS than for those without NS and that all CHD events and
deaths from CHD are between two and three times higher than
they are in the general population of the same age and sex. We
relied on a clinical diagnosis of angina or coronary insufficiency
in three NS subjects and four controls who did not have an MI.
We did require that ECG abnormalities for probable or definite
ischemia be based on a blind ECG reading and the use of the
Minnesota Codes [181. If we had considered other sequelae of
atherosclerotic cardiovascular diseases in our definition of
CHD outcomes, our risk estimates would have been somewhat
higher. Furthermore, we did not include in our analysis data
from 13 NS subjects who had evidence of CHD before NS
diagnosis. If some of this disease was in fact associated with NS
which had not been diagnosed, the results would have been still
more striking. Excluding persons with minimal change disease
or other diagnoses with known independent higher risk of CHD
did not substantially alter the level of risk.
The few previous attempts to describe how NS and CHD are
related produced inconsistent results and generated disagree-
ment among authorities about whether NS increases CHD risk.
Of at least four published reports [6, 7, 9, 11] and data presented
in two letters [8, 10], three small studies and one large study
found no increased risk of CHD. However, all these reports had
methodologic shortcomings or depended on a small number of
subjects and were therefore of limited reliability. The two
studies which showed an increased risk were based on a small
series of only 15 [6] and 17 [7] subjects from tertiary referral
centers, and they used large and relatively undefined popula-
tions for comparison [20]. The estimates from Berlyne and
Mallick [6] that risk is increased 85 times and from Alexander,
Schapel and Edwards [7] that CHD will develop in 53% of NS
patients were much higher than our current modestly elevated
estimate and were substantially less reliable because they
depended on small numbers of subjects. The studies that
showed no increased risk included slightly more cases (N = 18
to 49) [8—11] but had insufficient follow-up and reflected the
possible blunting effect of including a high proportion of pa-
tients with minimal change disease [5]. Moreover, these studies
either had no control group or failed to control for the potential
confounding effects of smoking and hypertension. The single
large study by Wass et al [11], although roughly the same size as
our current study, found that 27% of subjects had minimal
change disease. The inconsistent results of these studies have
led two leading authorities to support opposing arguments
about the association between NS and CHD [12, 20].
In the absence of firm epidemiologic evidence, those who
believe that the association exists have relied on the biologic
plausibility of an increased risk of CHD in NS patients. Fifty
percent or more NS patients are known to have elevated serum
cholesterol or low-density lipoprotein (LDL) levels, or both [5},
and hypercholesterolemia is recognized as a major risk factor
for MI and other forms of cardiovascular disease [211. In
patients with NS, hyperlipidemia could accelerate progression
of atherosclerosis and increase platelet aggregation. Frequent
hypertension and use of steroids in therapy can further increase
CHD risk. Given this line of evidence, reinforced by increased
safety and effectiveness of modern antihyperlipidemic medica-
tions, authorities now advocate pharmacologic treatment of the
hyperlipidemia of NS [4, 5, 22—25].
Our data did not allow us to elucidate the particular charac-
teristics of NS which may be responsible for the increased risks
we observed. Our primary analysis was directed at determining
whether CHD incidence and mortality were elevated among
persons with NS when compared with those for the general
population. We did not intend to determine what specific aspect
of NS (that is, hypercholesterolemia, hypertriglyceridemia, or
hypertension) conferred the most risk because our retrospec-
tive medical record review data were inadequate for key
variables like cholesterol levels. However, because one of the
most likely features of NS which could contribute to increased
CHD risk is hyperlipidemia, we believed it appropriate to
exclude the cholesterol level from the model. Thus, the risk we
report can be interpreted as the additional CHD risk posed by
having NS after adjusting for effects of age, sex, hypertension,
and smoking. We cannot determine what residual risk might
exist after controlling for hyperlipidemia. Even if we had lipid
level data for all subjects, hyperlipidemia and NS are so closely
associated that it would not be possible to determine their
separate effects on CHD risk.
One reason that direct evidence of an association between
NS and CHD has been difficult to establish is that appropriate
studies are difficult to perform [26]. Among other things, large
numbers of patients are needed and must be available for
reasonably long follow-up. We previously estimated the annual
incidence of hospitalization for NS in our population at only
2.6/100,000 members [14]. In our study, we searched for all
patients hospitalized with NS from 1971 through 1981 in a large,
well-defined population that grew from I million to about 1.8
million during that period. The search was facilitated by com-
puter-stored diagnoses since 1976 and hospital discharge logs
dating back to the early 1950s. The membership we studied
received primary through tertiary care within the comprehen-
sive health plan. Any selection bias in the group of NS subjects
studied was thus minimal compared with that of studies from
referral centers. We selected a contemporaneous control group,
matched for age and sex, from the same membership popula-
tion. Control subjects had access to the same medical care
system as persons with NS. We accumulated a mean 5.6 years
of follow-up for CHD morbidity while subjects were in the
health plan and a mean 12.1 years for the mortality follow-up.
We were further able to obtain data on possible confounding
factors such as hypertension and smoking in most subjects.
The limitations of our study were primarily a feature of the
retrospective nature of the data collected from medical records.
Medical care was not delivered nor were laboratory evaluations
done in any standard fashion. Because few control subjects had
serious diagnosed diseases, the possibility of finding evidence
of angina, ECG abnormalities, and coronary insufficiency may
have been more rare for them than for persons with NS.
However, we do not believe that acute MI or deaths were less
likely to have been recognized in control subjects than in
research subjects. Additionally, our cholesterol level data were
insufficient to analyze the risk by specific lipid levels or by
duration of hyperlipidemia. Finally, in our analysis of nonfatal
CHD events, we began follow-up at the date of NS diagnosis,
even though 40 (28%) occurred before 1/1/71, which was the
date after which we could identify persons with the disease
from our computer-stored records. This circumstance means
that the nature of nonfatal CHD events occurring before 1/1/71
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among persons who died before that date may have differed
from those occurring after that date. Nevertheless, no bias
exists between NS subjects and their controls because both
were analytically treated alike. Furthermore, even if certain
CHD events were not recorded, they would probably have been
more numerous among the NS subjects than among the controls
and would only have increased the relative risks we have
reported,
As in the large study by Wass et al [11], we excluded from
follow-up NS subjects who had reached ESRD and in whom
either dialysis was initiated or transplants were done. Despite
concern that this approach [5] may not identify a possible
increased risk of CHD after terminal failure [27], our study
found that of the 14 deaths among the 29 patients with ESRD
treated by hemodialysis, none was clearly secondary to CHD.
Some investigators have argued that the decision to treat the
hyperlipidemia of NS rests on two types of evidence: (1) that
the risk of CHD is increased in NS patients and, (2) that the
necessary medications are reasonably safe and effective [28].
Other factors, such as the substantial comorbidity among NS
patients reflected in the high overall mortality observed in this
group and the complexity of existing therapeutic regimens,
must also be considered. Our study suggests that at least the
current assumption about increased CHD risk among persons
with NS is valid. Further work will be needed to evaluate the
factors that contribute to this increased risk.
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